121 related articles for article (PubMed ID: 22921183)
1. Phase I dose-escalation study of intravenous aflibercept administered in combination with irinotecan, 5-fluorouracil and leucovorin in patients with advanced solid tumours.
Van Cutsem E; Khayat D; Verslype C; Billemont B; Tejpar S; Meric JB; Soussan-Lazard K; Assadourian S; Cartot-Cotton S; Rixe O
Eur J Cancer; 2013 Jan; 49(1):17-24. PubMed ID: 22921183
[TBL] [Abstract][Full Text] [Related]
2. Intravenous aflibercept administered in combination with irinotecan, 5-fluorouracil and leucovorin in patients with advanced solid tumours: results from the expansion cohort of a phase I study.
Khayat D; Tejpar S; Spano JP; Verslype C; Bloch J; Vandecaveye V; Assadourian S; Soussan-Lazard K; Cartot-Coton S; Van Cutsem E
Eur J Cancer; 2013 Mar; 49(4):790-7. PubMed ID: 23312881
[TBL] [Abstract][Full Text] [Related]
3. A phase I study of intravenous aflibercept with FOLFIRI in Japanese patients with previously treated metastatic colorectal cancer.
Yoshino T; Yamazaki K; Yamaguchi K; Doi T; Boku N; Machida N; Onozawa Y; Asayama M; Fujino T; Ohtsu A
Invest New Drugs; 2013 Aug; 31(4):910-7. PubMed ID: 23179335
[TBL] [Abstract][Full Text] [Related]
4. Phase I Dose-Escalation and Pharmacokinetic Study of Intravenous Aflibercept in Combination with Docetaxel, Cisplatin, and 5-Fluorouracil in Patients with Advanced Solid Malignancies.
Bahleda R; Baker J; Massard C; Gadgeel SM; Rogers JE; Izzedine H; Deutsch E; Garris JL; Khan A; Boelle E; Assadourian S; Soria JC; Ajani JA
Oncology; 2016; 90(1):10-20. PubMed ID: 26492090
[TBL] [Abstract][Full Text] [Related]
5. A phase I and pharmacokinetic study of afilbercept with FOLFIRI: comparison of Chinese and Caucasian populations.
Xu J; Li Y; Sun X; Zhang D; Liu R; Ziti-Ljajic S; Shi D; Xue F; Le Bail N; Xu R
Invest New Drugs; 2017 Aug; 35(4):463-470. PubMed ID: 28102464
[TBL] [Abstract][Full Text] [Related]
6. Phase I trial of irinotecan, infusional 5-fluorouracil, and leucovorin (FOLFIRI) with erlotinib (OSI-774): early termination due to increased toxicities.
Messersmith WA; Laheru DA; Senzer NN; Donehower RC; Grouleff P; Rogers T; Kelley SK; Ramies DA; Lum BL; Hidalgo M
Clin Cancer Res; 2004 Oct; 10(19):6522-7. PubMed ID: 15475439
[TBL] [Abstract][Full Text] [Related]
7. Phase I dose-escalation study of intravenous aflibercept in combination with docetaxel in patients with advanced solid tumors.
Isambert N; Freyer G; Zanetta S; You B; Fumoleau P; Falandry C; Favier L; Assadourian S; Soussan-Lazard K; Ziti-Ljajic S; Trillet-Lenoir V
Clin Cancer Res; 2012 Mar; 18(6):1743-50. PubMed ID: 22261804
[TBL] [Abstract][Full Text] [Related]
8. Fluorouracil, leucovorin and irinotecan associated with aflibercept can induce microscopic colitis in metastatic colorectal cancer patients.
Ghiringhelli F; Vincent J; Beltjens F; Bengrine L; Ladoire S
Invest New Drugs; 2015 Dec; 33(6):1263-6. PubMed ID: 26490656
[TBL] [Abstract][Full Text] [Related]
9. Aflibercept for metastatic colorectal cancer: safety data from the Spanish named patient program.
Salgado Fernández M; Pérez Hoyos MT; Díaz de Corcuera I; Vidal Arbués A; García de la Torre M
Expert Opin Drug Saf; 2015 Aug; 14(8):1171-9. PubMed ID: 26076885
[TBL] [Abstract][Full Text] [Related]
10. Biweekly chemotherapy with oxaliplatin, irinotecan, infusional Fluorouracil, and leucovorin: a pilot study in patients with metastatic colorectal cancer.
Falcone A; Masi G; Allegrini G; Danesi R; Pfanner E; Brunetti IM; Di Paolo A; Cupini S; Del Tacca M; Conte P
J Clin Oncol; 2002 Oct; 20(19):4006-14. PubMed ID: 12351598
[TBL] [Abstract][Full Text] [Related]
11. Aflibercept versus placebo in combination with fluorouracil, leucovorin and irinotecan in the treatment of previously treated metastatic colorectal cancer: prespecified subgroup analyses from the VELOUR trial.
Tabernero J; Van Cutsem E; Lakomý R; Prausová J; Ruff P; van Hazel GA; Moiseyenko VM; Ferry DR; McKendrick JJ; Soussan-Lazard K; Chevalier S; Allegra CJ
Eur J Cancer; 2014 Jan; 50(2):320-31. PubMed ID: 24140268
[TBL] [Abstract][Full Text] [Related]
12. A phase 1 dose-escalation study of veliparib with bimonthly FOLFIRI in patients with advanced solid tumours.
Berlin J; Ramanathan RK; Strickler JH; Subramaniam DS; Marshall J; Kang YK; Hetman R; Dudley MW; Zeng J; Nickner C; Xiong H; Komarnitsky P; Shepherd SP; Hurwitz H; Lenz HJ
Br J Cancer; 2018 Apr; 118(7):938-946. PubMed ID: 29527010
[TBL] [Abstract][Full Text] [Related]
13. Bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: a phase 2 trial.
Masi G; Loupakis F; Salvatore L; Fornaro L; Cremolini C; Cupini S; Ciarlo A; Del Monte F; Cortesi E; Amoroso D; Granetto C; Fontanini G; Sensi E; Lupi C; Andreuccetti M; Falcone A
Lancet Oncol; 2010 Sep; 11(9):845-52. PubMed ID: 20702138
[TBL] [Abstract][Full Text] [Related]
14. A phase I/II study of irinotecan when added to 5-fluorouracil and leucovorin and pelvic radiation in locally advanced rectal cancer: a Colorectal Clinical Oncology Group Study.
Glynne-Jones R; Falk S; Maughan TS; Meadows HM; Sebag-Montefiore D
Br J Cancer; 2007 Feb; 96(4):551-8. PubMed ID: 17262086
[TBL] [Abstract][Full Text] [Related]
15. A phase I dose-escalation study of PEP02 (irinotecan liposome injection) in combination with 5-fluorouracil and leucovorin in advanced solid tumors.
Chiang NJ; Chao TY; Hsieh RK; Wang CH; Wang YW; Yeh CG; Chen LT
BMC Cancer; 2016 Nov; 16(1):907. PubMed ID: 27871319
[TBL] [Abstract][Full Text] [Related]
16. Randomized phase III trial comparing biweekly infusional fluorouracil/leucovorin alone or with irinotecan in the adjuvant treatment of stage III colon cancer: PETACC-3.
Van Cutsem E; Labianca R; Bodoky G; Barone C; Aranda E; Nordlinger B; Topham C; Tabernero J; André T; Sobrero AF; Mini E; Greil R; Di Costanzo F; Collette L; Cisar L; Zhang X; Khayat D; Bokemeyer C; Roth AD; Cunningham D
J Clin Oncol; 2009 Jul; 27(19):3117-25. PubMed ID: 19451425
[TBL] [Abstract][Full Text] [Related]
17. Safety and Management of Toxicity Related to Aflibercept in Combination with Fluorouracil, Leucovorin and Irinotecan in Malaysian Patients with Metastatic Colorectal Cancer.
Yusof MM; Abdullah NM; Sharial MM; Zaatar A
Asian Pac J Cancer Prev; 2016; 17(3):973-8. PubMed ID: 27039822
[TBL] [Abstract][Full Text] [Related]
18. Aflibercept Plus FOLFIRI in the Real-life Setting: Safety and Quality of Life Data From the Italian Patient Cohort of the Aflibercept Safety and Quality-of-Life Program Study.
Pastorino A; Di Bartolomeo M; Maiello E; Iaffaioli V; Ciuffreda L; Fasola G; Di Costanzo F; Frassineti GL; Marchetti P; Antoniotti C; Leone F; Zaniboni A; Aprile G; Zilocchi C; Sobrero A; Bordonaro R
Clin Colorectal Cancer; 2018 Sep; 17(3):e457-e470. PubMed ID: 29605592
[TBL] [Abstract][Full Text] [Related]
19. Phase I trial of UFT/leucovorin and irinotecan in patients with advanced cancer.
Veronese ML; Stevenson JP; Sun W; Redlinger M; Algazy K; Giantonio B; Hahn S; Vaughn D; Thorn C; Whitehead AS; Haller DG; O'Dwyer PJ
Eur J Cancer; 2004 Mar; 40(4):508-14. PubMed ID: 14962716
[TBL] [Abstract][Full Text] [Related]
20. Phase I and pharmacokinetic study of two different schedules of oxaliplatin, irinotecan, Fluorouracil, and leucovorin in patients with solid tumors.
Goetz MP; Erlichman C; Windebank AJ; Reid JM; Sloan JA; Atherton P; Adjei AA; Rubin J; Pitot H; Galanis E; Ames MM; Goldberg RM
J Clin Oncol; 2003 Oct; 21(20):3761-9. PubMed ID: 12963697
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
